Bring VYD2311 to Canada: Protect Immunocompromised People & Fund Long COVID Trials
The Issue
Bring VYD2311 to Canada: Protect Immunocompromised People & Support Long COVID Clinical Trials
The COVID-19 pandemic is not over, yet the sustained public-health action needed to address its ongoing consequences remains inadequate.
SARS-CoV-2 continues to circulate, evolve, and cause severe illness, deaths, and Long COVID. Despite these ongoing risks, essential protections have been scaled back, access to preventive treatments remains limited, and investment in research addressing the underlying causes of Long COVID has not matched the scale of the problem.
The World Health Organization ended COVID-19's international public-health emergency designation in May 2023, but that decision did not mean the threat had disappeared. In August 2026, the WHO continued to classify COVID-19 as a moderate global public-health risk, emphasizing its ongoing impact on vulnerable populations. [1]
For Canadians who are immunocompromised, vaccination alone may not provide adequate protection. Meanwhile, those living with Long COVID continue to face substantial disability, limited treatment options, and an urgent need for biomedical research.
Canada must do more than acknowledge these challenges. It must take meaningful, coordinated action to prevent infections, protect vulnerable populations, and accelerate the development of effective treatments.
We are calling on Health Canada and federal and provincial governments to support timely access to VYD2311, a promising next-generation monoclonal antibody, if approved, while investing in clinical trials investigating the biological causes of Long COVID.
VYD2311: A Promising New Approach to COVID-19 Prevention
Many Canadians living with cancer, organ transplants, autoimmune diseases requiring immunosuppressive treatment, and other causes of moderate to severe immunocompromise remain particularly vulnerable to COVID-19.
For some, vaccination alone may not provide sufficient protection.
Monoclonal antibodies offer a potentially important additional layer of protection by delivering ready-made antibodies capable of neutralizing SARS-CoV-2, provided they remain effective against circulating variants.
VYD2311, developed by Invivyd, is an investigational next-generation monoclonal antibody designed to neutralize SARS-CoV-2, including contemporary variants.
Its development program includes two major Phase 3 clinical trials:
- DECLARATION: A randomized, placebo-controlled trial investigating VYD2311 for preventing symptomatic COVID-19, including the potential duration of protection following intramuscular administration. [2]
- LIBERTY: A randomized trial evaluating safety, tolerability, and neutralizing antibody responses, including when VYD2311 is administered alongside a COVID-19 vaccine. [3]
In September 2026, Invivyd reported positive Phase 3 LIBERTY safety and tolerability results, alongside encouraging neutralizing antibody findings. These are important developments, although clinical protection against COVID-19 still requires definitive evaluation.
VYD2311 has not yet been authorized for routine clinical use in Canada.
Health Canada should proactively engage with Invivyd to establish a clear regulatory pathway and prepare for timely, equitable Canadian access if the available evidence supports authorization.
Canadians should not have to rely on travelling internationally or paying substantial out-of-pocket costs to access essential preventive treatments.
FLINTLOCK: Investigating VYD2311 for Long COVID
In October 2026, Invivyd and the SPEAR (Spike Protein Elimination and Recovery) Study Group announced FLINTLOCK, a Phase 2 clinical trial investigating VYD2311 as a potential treatment for Long COVID or post-vaccination syndrome.
Officially registered on ClinicalTrials.gov on October 27, the study is expected to enroll approximately 130 participants.
FLINTLOCK will investigate whether repeated high-dose administration of VYD2311 is safe and can produce meaningful clinical improvements. [4]
This represents encouraging progress toward developing treatments for Long COVID, an illness that continues to cause substantial disability without an established cure.
However, even if monoclonal antibodies successfully neutralize accessible SARS-CoV-2, they may not necessarily eliminate infected cells or viral material persisting within tissues.
This distinction is important when considering how future treatments should be developed.
Long COVID Requires Research Into Its Underlying Causes
An expanding body of scientific evidence suggests that SARS-CoV-2 or its components can persist in certain tissues after acute infection, potentially contributing to ongoing immune dysfunction in some patients.
A 2026 study published in Mucosal Immunology identified persistent SARS-CoV-2 nucleocapsid protein in intestinal tissue from people with post-COVID syndrome, alongside altered natural killer cell populations, increased mast-cell activity, and other signs of local immune dysregulation. [5]
Research published in Science Translational Medicine also identified persistent T-cell activation across multiple tissues, including the gut, lungs, bone marrow, brainstem, and spinal cord. Investigators additionally detected SARS-CoV-2 RNA in intestinal biopsies. [6]
These findings strengthen the rationale for investigating tissue-based viral persistence. However, detecting viral proteins or RNA does not necessarily demonstrate ongoing replication or establish that viral persistence causes every case of Long COVID.
A 2025 review published in The Lancet Infectious Diseases, titled Targeting the SARS-CoV-2 Reservoir in Long COVID, emphasized the importance of identifying viral reservoirs, developing reliable biomarkers, and investigating treatments matched to specific biological mechanisms. [7]
This research raises a fundamental question:
Could effective treatment require targeting several distinct mechanisms of viral persistence rather than relying on a single antiviral or monoclonal antibody?
Moving Toward Mechanism-Matched Treatments
Different forms of viral persistence may require fundamentally different therapeutic approaches.
Potential directions for future clinical trials include:
- Ongoing viral replication: Direct-acting antivirals such as remdesivir or ensitrelvir, potentially combined with pegylated interferon-lambda to strengthen intracellular antiviral defenses.
- Persistently infected cells: SARS-CoV-2-specific cytotoxic T-cell therapies, such as TVGN-489 developed by Tevogen Bio, could potentially recognize and eliminate infected cells displaying viral antigens. Early clinical research has demonstrated feasibility in acute COVID-19, although efficacy in established Long COVID remains unknown. [8]
- Infected cells evading immune recognition: Research has demonstrated that SARS-CoV-2 can suppress HLA expression, potentially reducing the ability of cytotoxic T cells to recognize infected cells. [9] Natural killer (NK) cell-directed approaches may therefore deserve investigation. Anktiva (N-803), an IL-15 receptor agonist capable of stimulating NK cells and CD8 T cells, is already being evaluated in the INTERRUPT-LC study at UCSF. [10]
- Persistent intracellular viral RNA: Future RNA-targeting technologies, including siRNA and antisense oligonucleotides, could potentially address forms of viral persistence that conventional antivirals may not effectively target.
These are experimental research directions, not established treatments for Long COVID. None has been proven to eradicate persistent SARS-CoV-2 reservoirs.
Nevertheless, their distinct mechanisms provide compelling reasons to investigate carefully selected combination therapies.
Future trials should incorporate biomarkers capable of determining what is persisting, where it is located, whether it is replicating, and whether an intervention successfully reduces the proposed disease mechanism.
Autoimmunity May Be Another Important Piece
Viral persistence is not the only biological mechanism deserving investigation.
A May 2026 study published in Cell demonstrated that transferring antibodies from people with Long COVID into mice could produce neurological and other symptom-related abnormalities. [11]
These findings strengthen the possibility that pathogenic autoantibodies contribute to illness in certain patient subgroups.
Targeted approaches, including intravenous immunoglobulin (IVIG) and B-cell-directed therapies, warrant further investigation in appropriately selected patients, although controlled studies have produced mixed or negative results and benefits in Long COVID remain unproven.
Importantly, viral persistence and autoimmunity may not be mutually exclusive.
Persistent viral antigens could theoretically contribute to ongoing immune dysfunction, meaning that successful treatment in some patients might require addressing both the underlying trigger and its downstream effects.
Canada needs clinical trials that investigate these mechanisms together, identify biologically distinct patient subgroups, and evaluate whether targeted treatments can produce meaningful, lasting recovery.
Canada Must Strengthen Its Regulatory and Public-Health Response
Health Canada already possesses regulatory mechanisms for expedited review and conditional authorization of promising therapies for serious medical conditions.
However, these processes must be transparent, responsive to evolving scientific evidence, and capable of addressing the needs of vulnerable populations.
Canada should clarify how clinical trial data, laboratory neutralization studies, and appropriately validated immunobridging evidence can support timely regulatory evaluation of new monoclonal antibodies, without compromising safety or scientific standards.
Federal and provincial governments must also coordinate procurement, reimbursement, and distribution so that authorization translates into meaningful patient access.
At the same time, Canada must acknowledge that COVID-19 remains an ongoing public-health threat.
Continued transmission, reinfections, and the risk of Long COVID demand sustained public-health action, including improved indoor air quality, accessible vaccines and preventive treatments, transparent surveillance, and greater investment in biomedical research.
Preventing new cases of Long COVID must remain a national priority alongside developing treatments for those already affected.
What We Are Calling For
1. Timely Canadian access to VYD2311.
Health Canada should proactively engage with Invivyd to evaluate VYD2311 as clinical evidence becomes available and establish a timely regulatory pathway if its safety and effectiveness are adequately demonstrated.
2. Equitable access to protective monoclonal antibodies.
Federal and provincial governments must coordinate procurement, funding, and distribution to ensure that immunocompromised Canadians can access effective preventive treatments without prohibitive financial barriers.
3. Regulatory flexibility and transparency.
Health Canada should clarify how appropriate clinical, neutralization, and immunobridging evidence may support the authorization of emerging monoclonal antibodies while maintaining rigorous safety and efficacy standards.
4. Publicly funded, mechanism-matched Long COVID clinical trials.
Federal and provincial governments should invest in collaborative, well-designed clinical trials investigating persistent viral reservoirs, targeted antiviral combinations, virus-specific cellular immunotherapies, autoimmune mechanisms, and other potential causes of Long COVID.
These trials should incorporate validated biomarkers wherever possible to identify relevant patient subgroups, evaluate treatment responses, and determine whether underlying disease mechanisms can be corrected.
5. Improved access to promising investigational treatments.
Canada should improve awareness and accessibility of existing special-access and clinical-trial pathways for eligible patients when standard treatments are unavailable or unsuitable, with appropriate medical oversight and safeguards.
6. Meaningful patient involvement.
People living with Long COVID and those who are immunocompromised must have meaningful representation in clinical trial design, research priorities, public-health policy, and decisions affecting access to prevention and treatment.
7. Continued COVID-19 prevention and surveillance.
Canada must maintain credible SARS-CoV-2 surveillance, promote cleaner indoor air, ensure access to current vaccines and preventive therapies, and recognize the ongoing consequences of COVID-19 as a public-health priority.
What You Can Do
- Sign and share this petition to demonstrate that protecting vulnerable Canadians and advancing Long COVID research remain urgent priorities.
- Contact your Member of Parliament, provincial representatives, Health Canada, and the Public Health Agency of Canada to call for timely access to VYD2311, regulatory transparency, and sustained biomedical research funding.
- Contact Invivyd to express support for Canadian regulatory submissions and future access to VYD2311.
This petition originally focused on bringing Pemgarda to Canada. As scientific research and monoclonal antibody development have progressed, the campaign has evolved to prioritize VYD2311 and the broader need for sustainable access to effective COVID-19 protection.
The underlying mission remains unchanged.
We must act on both sides of this crisis: protecting Canadians from preventable infections while pursuing effective treatments for those already living with Long COVID.
Canada has the scientific expertise, healthcare infrastructure, and research capacity to contribute meaningfully to these efforts.
What is needed now is sustained commitment, coordinated action, and the political will to ensure that vulnerable populations are not left behind.
Sign this petition to demand timely access to promising COVID-19 monoclonal antibodies and meaningful investment in clinical trials targeting the biological causes of Long COVID.
#MAbsForCanadaNOW #ProtectImmunocompromised #SupportLongCOVIDTrials #COVID19IsNotOver
Supporting Research & Clinical Trials
1. World Health Organization — COVID-19 Global Risk Assessment, August 2026
https://www.who.int/publications/m/item/covid-19-global-risk-assessment--version-10
2. Invivyd — DECLARATION Phase 3 Trial of VYD2311 for COVID-19 Prevention
3. Invivyd — LIBERTY Phase 3 Clinical Trial Results, September 2026
4. FLINTLOCK Phase 2 Clinical Trial — VYD2311 for Long COVID
https://clinicaltrials.gov/study/NCT07899346
5. Persistent Gut-Immune Axis Dysregulation in Long-Term Post-COVID Syndrome — Mucosal Immunology, 2026
https://doi.org/10.1016/j.mucimm.2026.03.002
6. Tissue-Based T Cell Activation and Viral RNA Persist for Up to Two Years Following SARS-CoV-2 Infection — Science Translational Medicine, 2024
https://doi.org/10.1126/scitranslmed.adk3295
7. Targeting the SARS-CoV-2 Reservoir in Long COVID — The Lancet Infectious Diseases, 2025
https://doi.org/10.1016/S1473-3099(24)00769-2
8. Safety and Feasibility of Third-Party Cytotoxic T Lymphocytes for High-Risk Patients With COVID-19 — Blood Advances, 2024
https://doi.org/10.1182/bloodadvances.2024013344
9. SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression — Viruses, 2025
https://doi.org/10.3390/v17081083
10. INTERRUPT-LC — Anktiva (N-803) Clinical Trial
https://clinicaltrials.gov/study/NCT07108036
11. A Causal Link Between Autoantibodies and Neurological Symptoms in Long COVID — Cell, 2026
1,355
The Issue
Bring VYD2311 to Canada: Protect Immunocompromised People & Support Long COVID Clinical Trials
The COVID-19 pandemic is not over, yet the sustained public-health action needed to address its ongoing consequences remains inadequate.
SARS-CoV-2 continues to circulate, evolve, and cause severe illness, deaths, and Long COVID. Despite these ongoing risks, essential protections have been scaled back, access to preventive treatments remains limited, and investment in research addressing the underlying causes of Long COVID has not matched the scale of the problem.
The World Health Organization ended COVID-19's international public-health emergency designation in May 2023, but that decision did not mean the threat had disappeared. In August 2026, the WHO continued to classify COVID-19 as a moderate global public-health risk, emphasizing its ongoing impact on vulnerable populations. [1]
For Canadians who are immunocompromised, vaccination alone may not provide adequate protection. Meanwhile, those living with Long COVID continue to face substantial disability, limited treatment options, and an urgent need for biomedical research.
Canada must do more than acknowledge these challenges. It must take meaningful, coordinated action to prevent infections, protect vulnerable populations, and accelerate the development of effective treatments.
We are calling on Health Canada and federal and provincial governments to support timely access to VYD2311, a promising next-generation monoclonal antibody, if approved, while investing in clinical trials investigating the biological causes of Long COVID.
VYD2311: A Promising New Approach to COVID-19 Prevention
Many Canadians living with cancer, organ transplants, autoimmune diseases requiring immunosuppressive treatment, and other causes of moderate to severe immunocompromise remain particularly vulnerable to COVID-19.
For some, vaccination alone may not provide sufficient protection.
Monoclonal antibodies offer a potentially important additional layer of protection by delivering ready-made antibodies capable of neutralizing SARS-CoV-2, provided they remain effective against circulating variants.
VYD2311, developed by Invivyd, is an investigational next-generation monoclonal antibody designed to neutralize SARS-CoV-2, including contemporary variants.
Its development program includes two major Phase 3 clinical trials:
- DECLARATION: A randomized, placebo-controlled trial investigating VYD2311 for preventing symptomatic COVID-19, including the potential duration of protection following intramuscular administration. [2]
- LIBERTY: A randomized trial evaluating safety, tolerability, and neutralizing antibody responses, including when VYD2311 is administered alongside a COVID-19 vaccine. [3]
In September 2026, Invivyd reported positive Phase 3 LIBERTY safety and tolerability results, alongside encouraging neutralizing antibody findings. These are important developments, although clinical protection against COVID-19 still requires definitive evaluation.
VYD2311 has not yet been authorized for routine clinical use in Canada.
Health Canada should proactively engage with Invivyd to establish a clear regulatory pathway and prepare for timely, equitable Canadian access if the available evidence supports authorization.
Canadians should not have to rely on travelling internationally or paying substantial out-of-pocket costs to access essential preventive treatments.
FLINTLOCK: Investigating VYD2311 for Long COVID
In October 2026, Invivyd and the SPEAR (Spike Protein Elimination and Recovery) Study Group announced FLINTLOCK, a Phase 2 clinical trial investigating VYD2311 as a potential treatment for Long COVID or post-vaccination syndrome.
Officially registered on ClinicalTrials.gov on October 27, the study is expected to enroll approximately 130 participants.
FLINTLOCK will investigate whether repeated high-dose administration of VYD2311 is safe and can produce meaningful clinical improvements. [4]
This represents encouraging progress toward developing treatments for Long COVID, an illness that continues to cause substantial disability without an established cure.
However, even if monoclonal antibodies successfully neutralize accessible SARS-CoV-2, they may not necessarily eliminate infected cells or viral material persisting within tissues.
This distinction is important when considering how future treatments should be developed.
Long COVID Requires Research Into Its Underlying Causes
An expanding body of scientific evidence suggests that SARS-CoV-2 or its components can persist in certain tissues after acute infection, potentially contributing to ongoing immune dysfunction in some patients.
A 2026 study published in Mucosal Immunology identified persistent SARS-CoV-2 nucleocapsid protein in intestinal tissue from people with post-COVID syndrome, alongside altered natural killer cell populations, increased mast-cell activity, and other signs of local immune dysregulation. [5]
Research published in Science Translational Medicine also identified persistent T-cell activation across multiple tissues, including the gut, lungs, bone marrow, brainstem, and spinal cord. Investigators additionally detected SARS-CoV-2 RNA in intestinal biopsies. [6]
These findings strengthen the rationale for investigating tissue-based viral persistence. However, detecting viral proteins or RNA does not necessarily demonstrate ongoing replication or establish that viral persistence causes every case of Long COVID.
A 2025 review published in The Lancet Infectious Diseases, titled Targeting the SARS-CoV-2 Reservoir in Long COVID, emphasized the importance of identifying viral reservoirs, developing reliable biomarkers, and investigating treatments matched to specific biological mechanisms. [7]
This research raises a fundamental question:
Could effective treatment require targeting several distinct mechanisms of viral persistence rather than relying on a single antiviral or monoclonal antibody?
Moving Toward Mechanism-Matched Treatments
Different forms of viral persistence may require fundamentally different therapeutic approaches.
Potential directions for future clinical trials include:
- Ongoing viral replication: Direct-acting antivirals such as remdesivir or ensitrelvir, potentially combined with pegylated interferon-lambda to strengthen intracellular antiviral defenses.
- Persistently infected cells: SARS-CoV-2-specific cytotoxic T-cell therapies, such as TVGN-489 developed by Tevogen Bio, could potentially recognize and eliminate infected cells displaying viral antigens. Early clinical research has demonstrated feasibility in acute COVID-19, although efficacy in established Long COVID remains unknown. [8]
- Infected cells evading immune recognition: Research has demonstrated that SARS-CoV-2 can suppress HLA expression, potentially reducing the ability of cytotoxic T cells to recognize infected cells. [9] Natural killer (NK) cell-directed approaches may therefore deserve investigation. Anktiva (N-803), an IL-15 receptor agonist capable of stimulating NK cells and CD8 T cells, is already being evaluated in the INTERRUPT-LC study at UCSF. [10]
- Persistent intracellular viral RNA: Future RNA-targeting technologies, including siRNA and antisense oligonucleotides, could potentially address forms of viral persistence that conventional antivirals may not effectively target.
These are experimental research directions, not established treatments for Long COVID. None has been proven to eradicate persistent SARS-CoV-2 reservoirs.
Nevertheless, their distinct mechanisms provide compelling reasons to investigate carefully selected combination therapies.
Future trials should incorporate biomarkers capable of determining what is persisting, where it is located, whether it is replicating, and whether an intervention successfully reduces the proposed disease mechanism.
Autoimmunity May Be Another Important Piece
Viral persistence is not the only biological mechanism deserving investigation.
A May 2026 study published in Cell demonstrated that transferring antibodies from people with Long COVID into mice could produce neurological and other symptom-related abnormalities. [11]
These findings strengthen the possibility that pathogenic autoantibodies contribute to illness in certain patient subgroups.
Targeted approaches, including intravenous immunoglobulin (IVIG) and B-cell-directed therapies, warrant further investigation in appropriately selected patients, although controlled studies have produced mixed or negative results and benefits in Long COVID remain unproven.
Importantly, viral persistence and autoimmunity may not be mutually exclusive.
Persistent viral antigens could theoretically contribute to ongoing immune dysfunction, meaning that successful treatment in some patients might require addressing both the underlying trigger and its downstream effects.
Canada needs clinical trials that investigate these mechanisms together, identify biologically distinct patient subgroups, and evaluate whether targeted treatments can produce meaningful, lasting recovery.
Canada Must Strengthen Its Regulatory and Public-Health Response
Health Canada already possesses regulatory mechanisms for expedited review and conditional authorization of promising therapies for serious medical conditions.
However, these processes must be transparent, responsive to evolving scientific evidence, and capable of addressing the needs of vulnerable populations.
Canada should clarify how clinical trial data, laboratory neutralization studies, and appropriately validated immunobridging evidence can support timely regulatory evaluation of new monoclonal antibodies, without compromising safety or scientific standards.
Federal and provincial governments must also coordinate procurement, reimbursement, and distribution so that authorization translates into meaningful patient access.
At the same time, Canada must acknowledge that COVID-19 remains an ongoing public-health threat.
Continued transmission, reinfections, and the risk of Long COVID demand sustained public-health action, including improved indoor air quality, accessible vaccines and preventive treatments, transparent surveillance, and greater investment in biomedical research.
Preventing new cases of Long COVID must remain a national priority alongside developing treatments for those already affected.
What We Are Calling For
1. Timely Canadian access to VYD2311.
Health Canada should proactively engage with Invivyd to evaluate VYD2311 as clinical evidence becomes available and establish a timely regulatory pathway if its safety and effectiveness are adequately demonstrated.
2. Equitable access to protective monoclonal antibodies.
Federal and provincial governments must coordinate procurement, funding, and distribution to ensure that immunocompromised Canadians can access effective preventive treatments without prohibitive financial barriers.
3. Regulatory flexibility and transparency.
Health Canada should clarify how appropriate clinical, neutralization, and immunobridging evidence may support the authorization of emerging monoclonal antibodies while maintaining rigorous safety and efficacy standards.
4. Publicly funded, mechanism-matched Long COVID clinical trials.
Federal and provincial governments should invest in collaborative, well-designed clinical trials investigating persistent viral reservoirs, targeted antiviral combinations, virus-specific cellular immunotherapies, autoimmune mechanisms, and other potential causes of Long COVID.
These trials should incorporate validated biomarkers wherever possible to identify relevant patient subgroups, evaluate treatment responses, and determine whether underlying disease mechanisms can be corrected.
5. Improved access to promising investigational treatments.
Canada should improve awareness and accessibility of existing special-access and clinical-trial pathways for eligible patients when standard treatments are unavailable or unsuitable, with appropriate medical oversight and safeguards.
6. Meaningful patient involvement.
People living with Long COVID and those who are immunocompromised must have meaningful representation in clinical trial design, research priorities, public-health policy, and decisions affecting access to prevention and treatment.
7. Continued COVID-19 prevention and surveillance.
Canada must maintain credible SARS-CoV-2 surveillance, promote cleaner indoor air, ensure access to current vaccines and preventive therapies, and recognize the ongoing consequences of COVID-19 as a public-health priority.
What You Can Do
- Sign and share this petition to demonstrate that protecting vulnerable Canadians and advancing Long COVID research remain urgent priorities.
- Contact your Member of Parliament, provincial representatives, Health Canada, and the Public Health Agency of Canada to call for timely access to VYD2311, regulatory transparency, and sustained biomedical research funding.
- Contact Invivyd to express support for Canadian regulatory submissions and future access to VYD2311.
This petition originally focused on bringing Pemgarda to Canada. As scientific research and monoclonal antibody development have progressed, the campaign has evolved to prioritize VYD2311 and the broader need for sustainable access to effective COVID-19 protection.
The underlying mission remains unchanged.
We must act on both sides of this crisis: protecting Canadians from preventable infections while pursuing effective treatments for those already living with Long COVID.
Canada has the scientific expertise, healthcare infrastructure, and research capacity to contribute meaningfully to these efforts.
What is needed now is sustained commitment, coordinated action, and the political will to ensure that vulnerable populations are not left behind.
Sign this petition to demand timely access to promising COVID-19 monoclonal antibodies and meaningful investment in clinical trials targeting the biological causes of Long COVID.
#MAbsForCanadaNOW #ProtectImmunocompromised #SupportLongCOVIDTrials #COVID19IsNotOver
Supporting Research & Clinical Trials
1. World Health Organization — COVID-19 Global Risk Assessment, August 2026
https://www.who.int/publications/m/item/covid-19-global-risk-assessment--version-10
2. Invivyd — DECLARATION Phase 3 Trial of VYD2311 for COVID-19 Prevention
3. Invivyd — LIBERTY Phase 3 Clinical Trial Results, September 2026
4. FLINTLOCK Phase 2 Clinical Trial — VYD2311 for Long COVID
https://clinicaltrials.gov/study/NCT07899346
5. Persistent Gut-Immune Axis Dysregulation in Long-Term Post-COVID Syndrome — Mucosal Immunology, 2026
https://doi.org/10.1016/j.mucimm.2026.03.002
6. Tissue-Based T Cell Activation and Viral RNA Persist for Up to Two Years Following SARS-CoV-2 Infection — Science Translational Medicine, 2024
https://doi.org/10.1126/scitranslmed.adk3295
7. Targeting the SARS-CoV-2 Reservoir in Long COVID — The Lancet Infectious Diseases, 2025
https://doi.org/10.1016/S1473-3099(24)00769-2
8. Safety and Feasibility of Third-Party Cytotoxic T Lymphocytes for High-Risk Patients With COVID-19 — Blood Advances, 2024
https://doi.org/10.1182/bloodadvances.2024013344
9. SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression — Viruses, 2025
https://doi.org/10.3390/v17081083
10. INTERRUPT-LC — Anktiva (N-803) Clinical Trial
https://clinicaltrials.gov/study/NCT07108036
11. A Causal Link Between Autoantibodies and Neurological Symptoms in Long COVID — Cell, 2026
Supporter Voices
Petition Updates
Share this petition
Petition created on April 9, 2025